Podcast: Gottlieb Addresses LDT Legislation At Brookings
Executive Summary
US FDA Commissioner Scott Gottlieb spoke with Medtech Insight about the agency’s decision to put the LDT issue to Congress instead of using guidance-making.
US FDA Commissioner Scott Gottlieb spoke at the Brookings Institution on March 20 about his departure from the agency. He noted that among the top issues that he hopes will be addressed after he leaves on April 5 are legislation addressing over-the-counter drugs and laboratory developed tests under an in vitro clinical test bill known as the VALID Act. Gottlieb also discussed FDA's decision to punt the issue to Congress instead of using guidance documents.
Listen to the podcast via the player below: